Literature DB >> 11553970

Familial Parkinson's disease. Alpha-synuclein and parkin.

Y Mizuno1, N Hattori, T Kitada, H Matsumine, H Mori, H Shimura, S Kubo, H Kobayashi, S Asakawa, S Minoshima, N Shimizu.   

Abstract

We have reviewed recent progress in establishing the function of alpha-synuclein and parkin in relation to nigral degeneration in autosomal dominant and autosomal recessive PD. Mutations of alpha-synuclein (Ala53Thr and Ala30Pro) cause a form of autosomal dominant PD with early onset. Parkin is a novel protein expressed in the cytoplasm, including the terminal regions and Golgi apparatus. Mutations of parkin cause a form of autosomal recessive young-onset PD (ARJP). Both proteins appear to be associated with fast axonal transport. In addition, in sporadic PD, normal alpha-synuclein shows an increased tendency to self-aggregate. Thus, altered axonal transport of presynaptic proteins appears to play a crucial role in neurodegeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553970

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  23 in total

Review 1.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 2.  Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

Authors:  Li Qian; Patrick M Flood; Jau-Shyong Hong
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

3.  Imbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's disease.

Authors:  Nilesh W Gaikwad; Daniel Murman; Cheryl L Beseler; Muhammad Zahid; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Biomarkers       Date:  2011-06-21       Impact factor: 2.658

Review 4.  Inflammation as a causative factor in the aetiology of Parkinson's disease.

Authors:  P S Whitton
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

Review 5.  Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease.

Authors:  Gunjan Joshi; Yanzhuang Wang
Journal:  Bioessays       Date:  2014-12-28       Impact factor: 4.345

Review 6.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

Review 7.  Neuroinflammation in Parkinson's disease.

Authors:  Jae-Kyung Lee; Thi Tran; Malú G Tansey
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-10       Impact factor: 4.147

8.  Updates in the pathophysiological mechanisms of Parkinson's disease: Emerging role of bone marrow mesenchymal stem cells.

Authors:  Hanaa H Ahmed; Ahmed M Salem; Hazem M Atta; Emad F Eskandar; Abdel Razik H Farrag; Mohamed A Ghazy; Neveen A Salem; Hadeer A Aglan
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 9.  Dopamine release in the basal ganglia.

Authors:  M E Rice; J C Patel; S J Cragg
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

10.  Loss of the golgin GM130 causes Golgi disruption, Purkinje neuron loss, and ataxia in mice.

Authors:  Chunyi Liu; Mei Mei; Qiuling Li; Peristera Roboti; Qianqian Pang; Zhengzhou Ying; Fei Gao; Martin Lowe; Shilai Bao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.